Genomics

Dataset Information

0

Phase I Clinical Trial Describing the Pharmacogenomics of Aspirin


ABSTRACT:

The study protocol for both cohorts has been previously described (Journal of Thrombosis and Thrombolysis 2012:1-12).

HV1 cohort: Briefly 50 healthy volunteers were exposed to two weeks of 325mg/day aspirin after which whole blood RNA was collected in PAXgene tubes and profiled by microarray before and after aspirin exposure. The pre-aspirin samples were profiled on the U133A 2.0 array and the post-aspirin samples were profiled on the U1333plus 2.0 array.

HV2 cohort: Briefly 53 healthy volunteers were exposed to four weeks of 325mg/day aspirin after which whole blood RNA was collected in PAXgene tubes and profiled by U133plus 2.0 array before and after aspirin exposure.

PROVIDER: phs000548.v1.p1 | EGA |

REPOSITORIES: EGA

altmetric image

Publications

Time-dependent changes in non-COX-1-dependent platelet function with daily aspirin therapy.

Voora Deepak D   Ortel Thomas L TL   Lucas Joseph E JE   Chi Jen-Tsan JT   Becker Richard C RC   Ginsburg Geoffrey S GS  

Journal of thrombosis and thrombolysis 20120401 3


To develop an integrated metric of non-COX-1-dependent platelet function (NCDPF) to measure the temporal response to aspirin in healthy volunteers and diabetics. NCDPF on aspirin demonstrates wide variability, despite suppression of COX-1. Although a variety of NCDPF assays are available, no standard exists and their reproducibility is not established. We administered 325 mg/day aspirin to two cohorts of volunteers (HV1, n = 52, and HV2, n = 96) and diabetics (DM, n = 74) and measured NCDPF usin  ...[more]

Similar Datasets

| phs000548 | dbGaP
2022-08-30 | GSE182482 | GEO
2024-02-26 | GSE216328 | GEO
2011-07-22 | GSE24757 | GEO
2016-02-24 | E-GEOD-78193 | biostudies-arrayexpress
2014-02-06 | GSE54740 | GEO
2022-04-01 | E-MTAB-5504 | biostudies-arrayexpress
2022-04-01 | E-MTAB-5505 | biostudies-arrayexpress
2016-11-15 | GSE89021 | GEO
2020-06-12 | GSE152255 | GEO